An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Latest Information Update: 09 Oct 2025
At a glance
- Drugs Emfizatamab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 26 Sep 2025 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.
- 18 Dec 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.